Back

Combination of an oral H2S donor to dapagliflozin provides additional therapeutic benefit in a cardiorenal model of heart failure with preserved ejection fraction (HFpEF)

31 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression Heart Failure ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Maria Antonietta Riemma

University of Campania Luigi Vanvitell, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Functional phenotyping combined with single-cell sequencing unmasks potential genes for hypercontractility in murine HFpEF
Mr T. Jeising (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Nuclear receptor co-repressor 1 promotes macrophage inflammation in heart failure with preserved ejection fraction: a translational study
Doctor E. Gorica (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Cell-type specific secretome profiling reveals targets of liver-heart interorgan crosstalk in HFpEF and semaglutide treatment
Doctor J. Schuette (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Disease-associated characteristics of cardiac endothelial cells and fibroblasts from a cardiomyocyte specific transgenic murine heart failure model
Mrs C. Redwanz (Greifswald, DE)
Abstract Slides Video
Presentation thumbnail
Establishment of a female HFpEF model using Dahl salt-sensitive rats and investigation of sympathetic activation-induced acute exacerbation of HFpEF
Doctor H. Nakashima (Fukuoka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression

The Event

Event poster

ESC Congress 2025

31 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction
thumbnail
Congress Presentation
The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report
thumbnail
Congress Presentation
Empagliflozin improves diastolic function in obese ZSF1 rats by restoring the cardiac mitochondrial respiratory capacity.

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources